Compare ATYR & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATYR | CCIF |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | 58 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 57.2M |
| IPO Year | N/A | N/A |
| Metric | ATYR | CCIF |
|---|---|---|
| Price | $0.51 | $2.80 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $3.67 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 102.1K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 25.90% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.40 | $2.57 |
| 52 Week High | $6.50 | $5.95 |
| Indicator | ATYR | CCIF |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 49.79 |
| Support Level | $0.46 | $2.57 |
| Resistance Level | $0.59 | $3.45 |
| Average True Range (ATR) | 0.03 | 0.08 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 79.50 | 61.11 |
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.